Express Pharma

Sophia Genetics partners with IDT to create NGS solutions in clinical diagnostics

3

The NGS bundles will be available immediately to more than 120 hospitals currently using the Sophia DDM platform

Sophia Genetics, a leader in Data-Driven Medicine (DDM), sign a strategic partnership with Integrated DNA Technologies (IDT). Under the terms of the agreement, Sophia Genetics will combine its Sophia DDM analytics platform with IDT’s next generation sequencing (NGS) target capture products. The new bundle will create the most advanced NGS data analytics platform in the market.

With these bundle solutions, Sophia Genetics aims to address the needs of European hospitals that are moving from small panels (1–20 genes) to medium panels (21–200 genes). The collaboration between the companies has reportedly produced a superior NGS target capture system that combines top analytical performance, high sample throughput, and flexibility.

Jurgi Camblong, CEO and founder of Sophia Genetics, commented, “The NGS bundle solutions are a true game changer for hospitals, relieving them of the burden of testing multiple NGS enrichment technologies. Having evaluated a large number of DNA enrichment technologies, we can now offer hospitals validated solutions that combine best-in-class target enrichment products with our advanced machine-learning based analytics. This will simplify validation of future NGS tests to meet hospitals’ needs for high quality diagnostics.”

Dr Joseph A Walder, IDT founder and CEO, commented, “We are proud of this partnership with Sophia Genetics. Sophia’s technology has triggered rapid advances in clinical genomics in recent years. With more labs and hospitals joining the clinical genomics community, we are confident Sophia Genetics is an ideal partner as we extend our target capture solutions to healthcare institutions in Europe for the ultimate benefit of patients.”

Reportedly, the first bundle solution to be launched will be for diagnosis of hereditary cancers, such as breast, ovarian, and colon cancers. Future solutions will target leukaemia and cardiac disease. With this partnership, Sophia Genetics and IDT aim to help hospitals address their need to adopt NGS tests for routine clinical diagnostics.

Comments are closed.